NAFLD in the 20’s. From Epidemiology to Management (PART - II)

Amedeo       Lonardo; Giovanni       Targher

doi:10.2174/138161282632200811172901

« Previous Next »

[1] 
Tovoli F, Ferri S, Piscaglia F. Hepatocellular carcinoma in non alcoholic fatty liver disease. Curr Pharm Des  2020; 26(32): 3909-14.
[2] 
Ballestri S, Tana C, Di Girolamo M, et al. Semi-quantitative ultrasonographic evaluation of NAFLD. Curr Pharm Des  2020; 26(32): 3915-27.
[3] 
Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The relevance of noninvasive tools to assess fibrosis in non-alcoholic fatty liver disease. Curr Pharm Des  2020; 26(32): 3928-38.

Download Options

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:NAFLD in the 20’s. From Epidemiology to Management (PART - II)

Volume: 26 Issue: 32

Author(s): Amedeo Lonardo and Giovanni Targher

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Lonardo Amedeo and Targher Giovanni , NAFLD in the 20’s. From Epidemiology to Management (PART - II), Current Pharmaceutical Design 2020; 26 (32) . https://dx.doi.org/10.2174/138161282632200811172901

DOI https://dx.doi.org/10.2174/138161282632200811172901	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286